Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | WDR5 | P61964 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2984400 | 0.88 | MAPT (0.54) | ACLYMEN1KMT2AMAPTLMNA | |
| SCHEMBL2990833 | 0.86 | ALDH1A1 (0.52) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL2989050 | 0.85 | SMN1; SMN2 (0.54) | ACLYMEN1KMT2AMAPTLMNA | |
| SCHEMBL2991716 | 0.85 | SMN1; SMN2 (0.54) | ACLYMEN1KMT2AMAPTLMNA | |
| SCHEMBL2985934 | 0.85 | ACLY (0.48) | ACLYMEN1KMT2AMAPTLMNA | |
| SCHEMBL2984160 | 0.83 | GHSR (0.53) | ACLYMEN1KMT2AMAPTLMNA | |
| SCHEMBL2989979 | 0.83 | GHSR (0.46) | ACLYMEN1KMT2AMAPTLMNA | |
| SCHEMBL2985942 | 0.83 | GHSR (0.53) | ACLYMEN1KMT2AMAPTLMNA | |
| SCHEMBL2992280 | 0.83 | ACLY (0.48) | ACLYMEN1KMT2AMAPTLMNA | |
| SCHEMBL2988757 | 0.82 | IDH1 (0.43) | ACLYMEN1KMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179168-A1 | ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS | BLANEY EMMA LOUISE | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179168-A1 | ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS | GHSR, GHRHR, GIPR | ACLY 2756/4885MEN1 1128/4885KMT2A 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.